Retatrutide: What It Is, Trial Results, Side Effects & How to Get It

The Quick Answer

At a Glance: What We Know Today

Retatrutide in One Minute

If you're short on time, here's what matters:

1. 1What it is: An investigational injectable medication that mimics three hormones to reduce appetite, slow digestion, and increase metabolism.
2. 2Who it's being studied for: Adults with obesity (BMI ≥30) or overweight with health conditions, with or without Type 2 diabetes.
3. 3What's exciting: Trial participants lost 24–29% of their body weight—more than any approved medication—with additional benefits for blood pressure, cholesterol, and joint pain.
4. 4What's still unknown: Long-term safety beyond 68 weeks, rare side effects, and how it performs in larger, more diverse populations.
5. 5What to do next: If you want to try retatrutide, search for recruiting clinical trials at ClinicalTrials.gov. If you need treatment now, talk to your doctor about FDA-approved alternatives like Wegovy or Zepbound.

Is Retatrutide FDA Approved?

As of January 2026, retatrutide remains an investigational medication. It cannot be legally prescribed by any doctor, dispensed by any pharmacy, or sold by any retailer in the United States or elsewhere. The only way to access retatrutide legally is by enrolling in a clinical trial.

What "Investigational" Actually Means

When a drug is investigational, it means:

• It has not completed the full regulatory review process
• The FDA has not confirmed it is safe and effective for general use
• No official prescribing information, dosing guidelines, or drug label exists
• Healthcare providers cannot legally prescribe it outside of research settings
• Insurance cannot cover it (because there's no approved indication)

Retatrutide is currently in Phase 3 clinical trials—the final stage before a company can apply for FDA approval. While Phase 3 results so far have been positive, more trials are ongoing, and the full safety and efficacy picture is still emerging.

Can Retatrutide Be Compounded?

Compounding pharmacies can sometimes create customized versions of FDA-approved medications. However, because retatrutide has never been approved, it does not qualify for compounding. Any pharmacy or clinic claiming to offer "compounded retatrutide" is operating outside FDA regulations.

When Could Retatrutide Be Available?

Here's the realistic timeline based on current trial completion dates and standard FDA review processes:

Important: This timeline reflects current information from Eli Lilly press releases. Retatrutide is still investigational. No official FDA approval date has been announced. Timing depends on trial completion, regulatory review, and manufacturing readiness.

What Is Retatrutide?

Retatrutide (research code: LY3437943) is an investigational medication being developed by Eli Lilly and Company for the treatment of obesity, Type 2 diabetes, and related conditions. It belongs to a new class of drugs called "triple agonists" because it activates three different hormone receptors in the body.

The Basics

• Developer: Eli Lilly and Company (also makers of Mounjaro and Zepbound)
• Research Code: LY3437943
• Brand Name: Not yet assigned (will be determined if/when FDA approved)
• Common Nicknames: "Triple-G" drug, "Triple agonist"
• Administration: Once-weekly subcutaneous injection (under the skin)
• Drug Class: GIP/GLP-1/Glucagon receptor agonist

Why Retatrutide Is Getting Attention

Retatrutide has generated significant interest because early clinical trials suggest it may produce greater weight loss than any currently approved medication:

The key difference is the glucagon receptor activation, which may increase metabolism and promote additional fat burning beyond what GLP-1 alone can achieve.

What Conditions Is Retatrutide Being Studied For?

Eli Lilly is running multiple Phase 3 trials (the TRIUMPH program) studying retatrutide for:

• Obesity and overweight (with or without weight-related health conditions)
• Type 2 diabetes (with obesity/overweight)
• Knee osteoarthritis (in people with obesity)
• Obstructive sleep apnea (in people with obesity)
• Metabolic dysfunction-associated steatotic liver disease (formerly NAFLD/NASH)
• Cardiovascular and kidney outcomes (long-term risk reduction)
• Chronic low back pain (in people with obesity)

How Does Retatrutide Work?

Retatrutide works by mimicking three natural hormones that regulate appetite, blood sugar, and metabolism. This "triple agonist" approach is what sets it apart from existing medications.

Visual representation of retatrutide's triple-agonist mechanism. Educational only.

The Three Hormone Receptors

Why Triple May Be Better Than Dual or Single

Think of it this way:

• SingleSemaglutide: Reduces appetite and slows digestion
• DualTirzepatide: Reduces appetite + improves insulin/fat metabolism
• TripleRetatrutide: Reduces appetite + improves metabolism + increases calorie burning

Each additional mechanism addresses a different aspect of weight regulation. The clinical trial data suggests these effects are additive—more targets, more weight loss. However, retatrutide has not been directly compared to tirzepatide or semaglutide in head-to-head trials. For a detailed comparison between the two, see our tirzepatide vs retatrutide guide.

Retatrutide Clinical Trial Results

The evidence for retatrutide comes from Phase 2 and Phase 3 clinical trials. Here's what the data shows.

Phase 2 Trial (NEJM, 2023)

The landmark Phase 2 trial was published in the New England Journal of Medicine in August 2023. This study established the foundation for retatrutide's development.

Phase 2 Weight Loss Results

Phase 3 TRIUMPH-4 Results (December 2025)

TRIUMPH-4 Weight Loss Results

Ongoing TRIUMPH Trials

Source: ClinicalTrials.gov. Additional trials studying sleep apnea, MASH, chronic low back pain, and long-term outcomes are also underway.

What We Still Don't Know

Retatrutide Side Effects and Safety

Like other GLP-1 medications, retatrutide's most common side effects are gastrointestinal. Here's what the clinical trials have shown.

Most Common Side Effects (TRIUMPH-4)

*Dysesthesia (tingling/numbness) is a new finding in Phase 3 trials that was not prominently reported in Phase 2. These events were generally mild and rarely led to stopping treatment. Source: PharmExec

For tips on managing GI side effects, see our GLP-1 side effect relief guide.

When Side Effects Typically Occur

• Are most common during the first few weeks of treatment
• Occur or worsen during dose increases (titration)
• Are rated as mild to moderate in severity
• Improve as the body adjusts to the medication
• Can be minimized by starting at a low dose and increasing slowly

Serious Side Effects (Rare)

Discontinuation Rates

In TRIUMPH-4:

• 12.2% on 9mg stopped due to adverse events
• 18.2% on 12mg stopped due to adverse events
• 4.0% on placebo stopped due to adverse events

Some discontinuations were due to "perceived excessive weight loss"—meaning some participants lost weight faster than they wanted.

Dosing Information

Trial Dosing Schedule (TRIUMPH-4 Protocol)

Because retatrutide is investigational, there is no FDA-approved dose. In TRIUMPH-4, participants started at 2 mg once weekly and were escalated in 4-week intervals to their assigned maintenance dose (9 mg or 12 mg), per protocol.

The gradual escalation helps minimize side effects. Clinical trials typically took 16-20 weeks to reach the target maintenance dose.

Note: Exact titration steps and timing can vary by study and participant tolerability. Refer to the specific trial protocol for full details. Source: PharmExec

Where to Get Retatrutide Safely

Retatrutide is not FDA approved and is not commercially available. For most people, the only legitimate way to access it today is through clinical trial enrollment. (In rare cases, investigational drugs may be available through regulated expanded access programs, but this depends on sponsor and regulator criteria.)

Infographic summary: The only legitimate pathway to retatrutide is through clinical trial enrollment at ClinicalTrials.gov. "Retatrutide peptide" sold online is unregulated, potentially contaminated, and illegal to sell for human use.

How to Find Clinical Trials

1. 1Visit ClinicalTrials.gov
2. 2Search "retatrutide" in the search bar
3. 3Filter by "Recruiting" status and your location
4. 4Review eligibility criteria for each trial
5. 5Contact the study coordinator via the provided information

Clinical Trial Eligibility Checklist

Based on typical trial criteria, candidates usually have:

If You're Not Eligible for a Trial

If you don't qualify for a clinical trial or prefer not to enroll, talk to your doctor about FDA-approved alternatives:

• Wegovy (semaglutide) — Single GLP-1 agonist, ~15-17% weight loss
• Zepbound (tirzepatide) — Dual GLP-1/GIP agonist, ~20-22% weight loss
• Saxenda (liraglutide) — Daily injection GLP-1 option

Compare GLP-1 providers to find the best option for your needs.

"Retatrutide Peptide" Online Warning

Red Flag Checklist: Signs of Unsafe Sources

Retatrutide vs. Tirzepatide vs. Semaglutide

Here's how retatrutide compares to the currently approved GLP-1 medications. For a deeper comparison of approved options, see our semaglutide vs. tirzepatide guide.

Decision Framework: Which Is Right for You?

Retatrutide Cost and Insurance

Since retatrutide isn't FDA approved, there's no official pricing yet. However, we can estimate based on similar medications:

For clinical trial participants: Study medication is provided free of charge during the trial period.

Should You Wait or Start Treatment Now?

This is a question many people are asking. Here's our honest take:

The bottom line: If you need treatment now and qualify for approved medications, there's no reason to wait. You can always switch to retatrutide later if it's approved and offers clear advantages for your situation. Obesity is a chronic condition that benefits from earlier intervention.

What Happens When You Stop Treatment?

Based on studies of similar medications, weight typically begins to return after stopping treatment. The extent of weight regain varies, but clinical trials show most people regain significant weight within a year.

For detailed information on what to expect after stopping GLP-1 medications, see our comprehensive guide: What happens when you stop taking GLP-1.

Key takeaway: Weight loss medications typically need to be continued to maintain results—similar to how blood pressure medications manage hypertension. They work best when combined with lifestyle changes (improved nutrition, increased physical activity).

Sources and References

Primary Sources

• New England Journal of Medicine (2023): Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med 2023;389:514-526. Read study
• Eli Lilly and Company (December 2025): "Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial." Press release | PRNewswire
• U.S. Food and Drug Administration: "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." FDA Warning
• ClinicalTrials.gov: Retatrutide clinical trial registry entries. View trials

Additional Clinical References

• The Lancet (2023): Rosenstock J, et al. "Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes." Lancet 2023;402:529-544.
• Nature Medicine (2024): Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease."
• Eli Lilly Official: "What to know about retatrutide." Read more

Comparative Clinical Trials

• SURMOUNT-1 (Tirzepatide): Jastreboff AM, et al. N Engl J Med 2022;387:205-216.
• STEP 1 (Semaglutide): Wilding JPH, et al. N Engl J Med 2021;384:989-1002.
• STEP 1 Extension (Semaglutide withdrawal): Wilding JPH, et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes Obes Metab 2022.

Editorial Standards

Update Log